BioSpace News Archive

Alpha Healthcare Acquisition Corp. III (Nasdaq: ALPA) (“ALPA”) today announced the successful completion of its business combination (the “Business Combination”) with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications (“Carmell”).

Neural Therapeutics Inc. (the “Company” or “Neural”), an ethnobotanical drug-discovery and development company, is pleased to announce that it has closed its previously announced rights offering which expired on July 7, 2023 (the “Rights Offering”).

Sales of SEK 905 (829) million, an increase of 9%, or 10% excluding discontinued business. In local currencies the growth was 3% and excluding discontinued business 4%.

Asensus Surgical, Inc. today announced that a leading United States-based hospital, has initiated a Senhance Surgical System program for use within their pediatric surgery department.

CureVac N.V. today announced that Dr. Igor Splawski, CureVac’s Chief Scientific Officer, will step down effective July 14, 2023 to return to early-stage research in the United States.

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted an approval from the Israeli Medical Cannabis Agency (“IMCA”) at the Israeli Ministry of Health to conduct its clinical trial for SCI-210 in children suffering from autism spectrum disorder (“ASD”).

Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.

Clario today announced the appointment of a new Chief Financial Officer, Jason Knoblauch, and three internal promotions to the Executive Leadership Team.

Astria Therapeutics, Inc. today announced that it will present information regarding patient preference for efficacy measures when starting on or switching to a new preventative therapy at the upcoming 2023 US Hereditary Angioedema Association (HAEA) National Summit in Orlando, Florida from July 20-23, 2023.

Universal PropTech Inc. (TSXV: UPI) (“UPI” or the “Company”) today announced that Chris Hazelton, President, Chief Executive Officer and director of UPI has resigned from the Company and the Board of Directors